Statins For Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis

Objective:To evaluate the effectiveness and safety of statins for vasospasm after aneurysmal subarachnoid hemorrhageMethods:We searched MEDLINE (1950-2009.9), EMBASE (1980-2009.9), CENTRAL (three quarter 2009), CBM (1978-2009.9), VIP(1989-2009.9), CNKI (1996-2009.9) for randomized controlled trials (RCT) relating to the use of statins for vasospasm after aneurysmal subarachnoid hemorrhage, languages are not confined. The search were conducted and extracted by the criteria, by two independent evaluators. Under the quality evaluation criteria of Cochrane Reviewer's Handbook 5.0 RCT, the quality of included studies was assessed. The software RevMan 5.0 was used for s tatistical analysis.Results:4 RCT were admitted after selection, and 190 participants were included in the review. The incidence of vasospasm[OR 0.48, 95%CI(0.27,0.88), P=0.02], vasospasm-related delayed ischemic deficits[OR 0.28,95% CI(0.11,0.73), P=0.009], and mortality[OR 0.30,95% CI(0.10,0.91), P=0.03] in the statins group were lower than the placebo group;and the adverse events was not significant between the tow groups.Conclusions:The use of statins after aneurysmal SAH significantly reduces the incidence of vasospasm, vasospasm-related delayed ischemic deficits, and mortality; and hasn't obviously adverse events. Statins for vasospasm after aneurysmal subarachnoid hemorrhage is feasible and safe. however, larger randomized, controlled trials are needed to confirm their safety and efficacy.